Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2014-08-20 Regulatory Filings
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Regeneus and Cryosite Partnership 2 pages 206.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 21 August 2014 about a partnership agreement between Regeneus and Cryosite for the development and manufacture of human stem cell products. It details the terms of the collaboration, the companies' roles, and future plans. There are no financial statements, regulatory certifications, voting results, or management changes. The content is a corporate announcement about a business partnership and collaboration, not a financial report, earnings release, or regulatory filing. The document length is 5778 characters, which is relatively short and typical for an announcement. Therefore, the most appropriate classification is a Regulatory Filing (RNS), as it is a general regulatory announcement that does not fit into more specific categories like Annual Report, Earnings Release, or M&A Activity.
2014-08-20 English
Patient Registry Update 2 pages 235.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 19 August 2014 from Regeneus Ltd, reporting interim clinical results from a patient registry study on their osteoarthritis cell therapy product, HiQCell. It provides specific data on patient outcomes at 1 and 2 years post-treatment, including pain reduction statistics and safety information. The document is relatively short (4582 characters) and is presented as an announcement of interim clinical results rather than a comprehensive financial or regulatory report. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is not a regulatory filing or certification, nor does it relate to governance, capital changes, or legal proceedings. The content focuses on clinical study results and product effectiveness updates, which are typically communicated via ASX announcements. Given the nature and length of the document, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit into other specific categories like financial reports or management information.
2014-08-18 English
Share Purchase Plan 10 pages 2.9MB
Capital/Financing Update Classification · 95% confidence The document is a detailed communication from Regeneus Ltd to its shareholders regarding a Share Purchase Plan (SPP). It includes terms and conditions, eligibility criteria, issue price, application instructions, key dates, and use of funds. The content focuses on a capital raising activity through issuing new shares to existing shareholders at a discount, with detailed procedural and regulatory information. There are no financial statements or earnings data, nor is it a report of voting results or management changes. It is not a regulatory filing or announcement of a report publication but a substantive update on financing activity. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2014-08-18 English
Successful $3M private placement & Cleansing Notice 2 pages 109.3KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the successful completion of a $3 million private placement capital raising by Regeneus Ltd. It includes details about the placement, participation by directors, and upcoming shareholder approval at the AGM. Additionally, there is a formal notification under section 708A(5)(e) of the Corporations Act regarding the issuance of shares pursuant to the placement. The content focuses on capital raising and share issuance activities rather than financial results, management changes, or regulatory certifications. The document length is 3622 characters, which is relatively short and typical for an announcement rather than a full report. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2014-08-14 English
Appendix 3B - Issue of Shares 12 pages 587.4KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3B' and contains detailed information about a new issue announcement, application for quotation of additional securities, and agreement. It includes specifics such as the class of securities issued, number of securities, issue price, purpose of the issue, and references to ASX rules and regulations. This type of document is a formal announcement related to capital raising activities and changes in the company's capital structure. It is not a full financial report, earnings release, or management discussion. The content aligns with announcements about new share issues or capital changes. Therefore, the document fits the category of 'Share Issue/Capital Change' (SHA). The document length is substantial (15,000 characters), indicating it is the announcement itself, not just a brief notice or report publication announcement. Confidence in this classification is high due to the clear presence of capital raising and securities issuance details.
2014-08-14 English
Appendix 3B - Issue of Options 12 pages 585.9KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements. It details the issuance of unlisted options, the number of securities issued, terms, and purpose of the issue (private placement to raise funds). The document is regulatory in nature, focused on capital raising and securities issuance, not a financial report or earnings release. It is not an annual or interim report, audit report, or management discussion. It is a formal capital/financing update announcing new securities issued and related details. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2014-08-14 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.